share_log

君实生物(01877.HK):第四代EGFR抑制剂WJ13404片临试申请获得批准

Jun Shi Bio (01877.HK): the application for the fourth generation EGFR inhibitor WJ13404 tablets was approved

Gelonghui Finance ·  Jun 13, 2022 18:00

Recently, Suzhou Junjing Biopharmaceutical Technology Co., Ltd., a subsidiary of the company, received the notice of approval of Drug Clinical Trials approved and issued by the State Drug Administration, and the application for clinical trials of the fourth generation EGFR inhibitor WJ13404 tablets (project code "JS113") was approved.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment